Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer

Curr Oncol. 2022 Aug 1;29(8):5466-5474. doi: 10.3390/curroncol29080432.

Abstract

We aimed to identify prognostic predictive factors of patients with penile squamous cell carcinoma (PSCC). This retrospective study reviewed the clinical and pathological data of patients with PSCC at 10 institutions in Japan between January 2008 and December 2019. The primary endpoint was cancer-specific survival (CSS). We also identified useful predictive factors for CSS in patients with PSCC. In total, 64 patients with PSCC were enrolled. At the end of the follow-up period, 15 patients (23.4%) died owing to PSCC and six (9.4%) died owing to other causes. The 2- and 3-year CSS rates were 78.9% and 76.6%, respectively. Using the Kaplan−Meier method, the Eastern Cooperative Oncology Group performance status 0, serum albumin levels ≥4.2 g/dL, hemoglobin levels ≥13.2 g/dL, C-reactive protein levels <0.21 mg/dL, clinical T stage ≤2, clinically negative lymph node (LN) status, and tumor size <30 mm were associated with a significantly better CSS. In the multivariate analysis, the clinically positive LN status was a significant predictive factor for CSS in patients with PSCC. Further prospective large-scale and long-term studies are required to validate our findings.

Keywords: cancer-specific survival; inflammatory markers; lymph node involvement; penile cancer.

MeSH terms

  • Carcinoma, Squamous Cell* / pathology
  • Epithelial Cells / pathology
  • Humans
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / pathology
  • Male
  • Penile Neoplasms* / pathology
  • Penile Neoplasms* / surgery
  • Prognosis
  • Retrospective Studies

Grants and funding

This research received no external funding.